#nivolumab

34 - Nivolumab in associazione a chemioterapia in prima linea per tumore dell’esofago a istologia squamosa

17 - Ipilimumab + nivolumab come trattamento di I linea nei pazienti con mesotelioma pleurico non resecabile a istologia non epitelioide

12 - Rimborsabilità di nivolumab+cabozantinib nel ca. del rene metastatico precedentemente non trattato (prima linea)

08 - Rimborsabilità di nivolumab + chemioterapia nel carcinoma gastroesofageo in prima linea

07 - Rimborsabilità di nivolumab + ipilimumab nel carcinoma del colon-retto MSI in seconda linea e oltre

03 - Rimborsabilità di nivolumab+ipilimumab nel trattamento del melanoma, carcinoma renale e NSCLC

01 - Nuove opzioni terapeutiche per la pratica clinica nel GI

Cancro al seno HER2+/HER2-low metastatico, promettente la combo trastuzumab deruxtecan più nivolumab

Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Squamous Lung Cancer, Part 4: Immunotherapy (audio)

Squamous Lung Cancer, Part 4: Immunotherapy (video)

Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials

Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials

Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?

Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer

Immunotherapy for Lung Cancer: General Concepts

Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

What is Immunotherapy & Its Mechanisms of Action?

Time to Response to Immunotherapy and the Concept of Pseudoprogression

The Current Role of Immunotherapy in the Treatment of Patients with Cancer

Managing Immunotherapy Side Effects

What is the Optimal Duration of Immunotherapy?

Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?

Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?

Immunotherapy for Lung Cancer

Immunotherapy for First Line Therapy of Advanced NSCLC

Data from Keynote 12 Nivolumab and Pembrolizumab

Immunotherapy for Small Cell Lung Cancer

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?